Compare RGCO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | ADAG |
|---|---|---|
| Founded | 1912 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 260.3M |
| IPO Year | 2005 | 2020 |
| Metric | RGCO | ADAG |
|---|---|---|
| Price | $23.62 | $4.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $22.70 | $8.25 |
| AVG Volume (30 Days) | 7.3K | ★ 218.8K |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 11.21 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $95,334,212.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $18.81 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.68 | $1.44 |
| 52 Week High | $26.63 | $4.75 |
| Indicator | RGCO | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 62.22 |
| Support Level | $20.80 | $3.21 |
| Resistance Level | N/A | $4.66 |
| Average True Range (ATR) | 0.81 | 0.37 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 47.52 | 80.57 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.